INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 -April 08, 2024 at 08:02 am EDT

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08,...

Related Keywords

Boca Raton ,Florida ,United States ,American ,David Moss ,Roxana Schillaci ,Gil Deza ,Jason Nelson ,Cordo Russo ,Maria Florencia Mercogliano ,Inmune Bio ,Joshua Schoonover ,Company Annual Report On Form ,Exchange Commission ,Inmune Bio Inc ,Company Current Reports On Form ,Nasdaq ,American Association Of Cancer Research ,Drug Administration ,Company Quarterly Reports On Form ,Dupont ,Overcome Resistance ,Enhance Therapeutic Outcome ,High Risk Breast ,American Association ,Cancer Research ,San Diego ,Inhibitory Molecules ,Sofia Bruni ,Expression Differences ,Metastatic Progression ,Lopez Della Vecchia ,General Counsel ,Dominant Negative Tumor Necrosis Factor ,Mild Alzheimer ,Mild Cognitive Impairment ,Natural Killer Cell Priming Platform ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Bio Contact ,